About: Vascular disrupting agent DMXAA enhances the antitumor effects generated by therapeutic HPV DNA vaccines

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Vascular disrupting agent DMXAA enhances the antitumor effects generated by therapeutic HPV DNA vaccines Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Vascular disrupting agent DMXAA enhances the antitumor effects generated by therapeutic HPV DNA vaccines
Creator	Hung, Chien-Fu Peng, Shiwen Wu, T-C Monie, Archana Pang, Xiaowu
Source	Medline; PMC
abstract	Antigen-specific immunotherapy using DNA vaccines has emerged as an attractive approach for the control of tumors. Another novel cancer therapy involves the employment of the vascular disrupting agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA). In the current study, we aimed to test the combination of DMXAA treatment with human papillomavirus type 16 (HPV-16) E7 DNA vaccination to enhance the antitumor effects and E7-specific CD8+ T cell immune responses in treated mice. We determined that treatment with DMXAA generates significant therapeutic effects against TC-1 tumors but does not enhance the antigen-specific immune responses in tumor bearing mice. We then found that combination of DMXAA treatment with E7 DNA vaccination generates potent antitumor effects and E7-specific CD8+ T cell immune responses in the splenocytes of tumor bearing mice. Furthermore, the DMXAA-mediated enhancement or suppression of E7-specific CD8+ T cell immune responses generated by CRT/E7 DNA vaccination was found to be dependent on the time of administration of DMXAA and was also applicable to other antigen-specific vaccines. In addition, we determined that inducible nitric oxide synthase (iNOS) plays a role in the immune suppression caused by DMXAA administration before DNA vaccination. Our study has significant implications for future clinical translation.
has issue date	2011-03-08(xsd:dateTime)
bibo:doi	10.1186/1423-0127-18-21
bibo:pmid	21385449
has license	cc-by
sha1sum (hex)	62b348dd9761ec78af4d53ad162a747cd300edce
schema:url	https://doi.org/10.1186/1423-0127-18-21
resource representing a document's title	Vascular disrupting agent DMXAA enhances the antitumor effects generated by therapeutic HPV DNA vaccines
has PubMed Central identifier	PMC3062584
has PubMed identifier	21385449
schema:publication	J Biomed Sci
resource representing a document's body	covid:62b348dd9761ec78af4d53ad162a747cd300edce#body_text
is schema:about of	named entity 'VASCULAR' named entity 'GENERATED' named entity 'HPV' named entity 'antitumor' named entity 'future' named entity 'generated' named entity 'ANTITUMOR' named entity 'COMBINATION' covid:arg/62b348dd9761ec78af4d53ad162a747cd300edce named entity 'EFFECTS' named entity 'HUMAN PAPILLOMAVIRUS TYPE 16' named entity 'IMMUNE RESPONSES' named entity 'THERAPEUTIC' named entity 'DOES NOT' named entity 'T CELL' named entity 'SUPPRESSION' named entity 'INDUCIBLE NITRIC OXIDE SYNTHASE' named entity 'TUMORS' named entity 'CAUSED BY' named entity 'SPLENOCYTES' named entity 'ANTIGEN' named entity 'CANCER THERAPY' named entity 'DNA VACCINATION' named entity 'NOVEL' named entity 'CD8' named entity 'STUDY' named entity 'HPV DNA' named entity 'MEDIATED' named entity 'CLINICAL' named entity 'TREATMENT' named entity 'ENHANCEMENT' named entity 'GENERATED' named entity 'EMPLOYMENT' named entity 'TC-1' named entity 'DMXAA' named entity 'DISRUPTING' named entity 'FOUND' named entity 'TO TEST' named entity 'ANTIGEN-SPECIFIC IMMUNOTHERAPY' named entity 'FUTURE' named entity 'AGENT' named entity 'PLAYS' named entity 'APPROACH' named entity 'USING' named entity 'BUT' named entity 'BEARING' named entity 'TRANSLATION' named entity 'SIGNIFICANT' named entity 'CRT' named entity 'TREATED' named entity 'TIME' named entity 'APPLICABLE' named entity 'THERAPEUTIC' named entity 'OUR' named entity 'MICE' named entity 'EFFECTS' named entity 'DEPENDENT' named entity 'TUMOR' named entity 'CONTROL' named entity 'ATTRACTIVE' named entity 'ADMINISTRATION' named entity 'ROLE' named entity 'ANTITUMOR' named entity 'AGENT' named entity 'DNA VACCINES' named entity 'DETERMINED' named entity 'SPECIFIC' named entity 'DMXAA' named entity 'ADDITION' named entity 'IMMUNE SUPPRESSION' named entity 'VASCULAR' named entity 'CURRENT' named entity 'VACCINES' named entity 'DISRUPTING' named entity 'ACETIC ACID' named entity 'ENHANCE' named entity 'DNA VACCINES'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software